Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Barange

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|November 21, 2023
Transition care to adolescent hepatology in a tertiary center for rare adult-child liver diseaseNolwenn Laborde, Karl Barange, Chloé Girard, et al.
Pharmacotherapy|November 13, 2004
Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapyHaleh Bagheri, Atoussa Fouladi, Karl Barange, et al.
Arzneimittel-Forschung|December 4, 2010
Influence of pre-analytical conditions on plasma ribavirin concentrationsPeggy Gandia, Stêphanie Trancart, Florence Nicot, et al.
Hepatology (Baltimore, Md.)|November 26, 2002
"A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleedingChristophe Bureau, Jean-Marie Péron, Laurent Alric, et al.
Journal of Gastroenterology and Hepatology|February 22, 2013
Impact of molecular adsorbent recirculating system on renal recovery in type-1 hepatorenal syndrome patients with chronic liver failureLaurence Lavayssière, Siba Kallab, Isabelle Cardeau-Desangles, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 20, 2008
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeksMaribel Rodriguez-Torres, Sugantha Govindarajan, Moises Diago, et al.
Clinical Transplantation|January 22, 2005
Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis CNassim Kamar, Jean-Sébastien Borde, Karine Sandres-Saune, et al.
Journal of Hepatology|June 6, 2006
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative casesJean-Pierre Zarski, Patrick Marcellin, Vincent Leroy, et al.
Mucosal Immunology|April 30, 2020
Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individualsManon Nayrac, Mary Requena, Claire Loiseau, et al.
Annals of Internal Medicine|October 16, 2013
Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trialFaouzi Saliba, Christophe Camus, François Durand, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie|November 21, 2023
Transition care to adolescent hepatology in a tertiary center for rare adult-child liver diseaseNolwenn Laborde, Karl Barange, Chloé Girard, et al.
Pharmacotherapy|November 13, 2004
Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapyHaleh Bagheri, Atoussa Fouladi, Karl Barange, et al.
Arzneimittel-Forschung|December 4, 2010
Influence of pre-analytical conditions on plasma ribavirin concentrationsPeggy Gandia, Stêphanie Trancart, Florence Nicot, et al.
Hepatology (Baltimore, Md.)|November 26, 2002
"A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleedingChristophe Bureau, Jean-Marie Péron, Laurent Alric, et al.
Journal of Gastroenterology and Hepatology|February 22, 2013
Impact of molecular adsorbent recirculating system on renal recovery in type-1 hepatorenal syndrome patients with chronic liver failureLaurence Lavayssière, Siba Kallab, Isabelle Cardeau-Desangles, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 20, 2008
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeksMaribel Rodriguez-Torres, Sugantha Govindarajan, Moises Diago, et al.
Clinical Transplantation|January 22, 2005
Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis CNassim Kamar, Jean-Sébastien Borde, Karine Sandres-Saune, et al.
Journal of Hepatology|June 6, 2006
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative casesJean-Pierre Zarski, Patrick Marcellin, Vincent Leroy, et al.
Mucosal Immunology|April 30, 2020
Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individualsManon Nayrac, Mary Requena, Claire Loiseau, et al.
Annals of Internal Medicine|October 16, 2013
Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trialFaouzi Saliba, Christophe Camus, François Durand, et al.
Pageof 4